RxDoctor Payments Data

Gene Zitser, MD

Neurology · Oakland Gardens, NYNPI 1710924964

Payments from drug & device makers

$21,743in general payments, 2019–2025

Across 1,019 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Teva Pharmaceuticals USA, Inc.$3K
  • UCB, Inc.$2K
  • Neurocrine Biosciences, Inc.$1K
  • Neurelis, Inc.$1K
  • Sanofi$761
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$1,3566%
  • Food & beverage$19,84391%
  • Education$5443%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)169$4,015
Teva Pharmaceuticals USA, Inc.128$2,706
UCB, Inc.92$1,727
Neurocrine Biosciences, Inc.83$1,468
Neurelis, Inc.33$1,124
Sanofi36$761
Biogen36$723
Supernus Pharmaceuticals, Inc.10$710
Pfizer36$708
SK Life Science, Inc.34$691
Eisai Inc.27$604
Harmony Biosciences LLC17$471
Scilex Pharmaceuticals Inc.34$449
Adamas Pharmaceuticals, Inc.19$402
Bristol Myers Squibb18$344
Amgen(2 entities)14$299
Lundbeck LLC12$268
Jazz Pharmaceuticals Inc.10$265
Avanir Pharmaceuticals, Inc.13$261
Medtronic(2 entities)6$235
Acadia Pharmaceuticals Inc10$228
Lilly USA, LLC12$227
Novartis14$222
Axsome Therapeutics, Inc.14$214
EMD Serono, Inc.11$210
Grifols USA, LLC10$206
Bausch Health US, LLC18$203
Collegium Pharmaceutical, Inc.9$179
Biohaven Pharmaceuticals, Inc.8$169
Amneal Pharmaceuticals LLC7$161
MDD US Operations, LLC10$153
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$149
Biohaven Pharmaceutical Holding Company Ltd.7$134
Sunovion Pharmaceuticals Inc.7$123
Corium, LLC6$119
Boston Scientific2$64
Acorda Therapeutics, Inc3$56
Argenx US, Inc.2$55
TG Therapeutics, Inc.2$47
AstraZeneca2$47
Aprecia Pharmaceuticals, LLC3$44
Kowa Pharmaceuticals America, Inc.3$42
Zyla Life Sciences, Inc.2$40
Redhill Biopharma Inc.2$40
Avion Pharmaceuticals2$39
Valinor Pharma, LLC2$37
Arbor Pharmaceuticals, Inc.2$34
Assertio Therapeutics, Inc.2$33
Merck2$33
Aquestive Therapeutics, Inc.2$32
Sumitomo Pharma America, Inc.1$29
E.r. Squibb & Sons, L.L.C.1$22
GRT US Holding, Inc.1$20
Catalyst Pharmaceuticals, Inc.1$20
Upsher-smith Laboratories LLC1$18
Livanova USA, Inc.1$18
Otsuka America Pharmaceutical, Inc.1$14
Promius Pharma LLC1$14
Virtus Pharmaceuticals LLC1$12
Forte Bio-pharma LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,743 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$181,601
Medicare patients
238
Services billed
3,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate15$140,575
NamzaricMemantine Hcl/Donepezil Hcl99$109,883
NuplazidPimavanserin Tartrate16$109,339
Nurtec OdtRimegepant Sulfate73$88,389
Droxidopa46$73,718
BotoxOnabotulinumtoxina43$66,999
NeuproRotigotine42$49,173
ZtlidoLidocaine24$28,044
UbrelvyUbrogepant28$27,623
Teriflunomide19$25,351
Aimovig AutoinjectorErenumab-Aooe28$24,766
Pregabalin661$22,191
Ajovy AutoinjectorFremanezumab-Vfrm30$21,040
OngentysOpicapone13$19,871
Memantine Hcl ErMemantine Hcl169$17,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric, Botox, Ubrelvy, Qulipta$4,015$221,598182 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$1,468$160,44528 claims
PfizerNurtec Odt, Relpax, Lyrica$708$116,637110 claims
Acadia Pharmaceuticals IncNuplazid$228$109,33916 claims
UCB, Inc.Neupro$1,727$49,17342 claims
Scilex Pharmaceuticals Inc.Ztlido$449$28,04424 claims
Redhill Biopharma Inc.Movantik$40$14,56734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.

Other neurology in Oakland Gardens

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →